Perhaps unsurprisingly, it appears to be true that “AR gain” (see below) does indeed lower overall survival (OS) and progression-free survival (PFS) rates among men with castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen, AR, ARSI, castration-resistant, CRPC, gain, inhibitor, receptor, signaling | 3 Comments »
On a CureTalks conversation earlier today with Dr. Carl June of the University of Pennsylvania (UPenn), we learned that his team had very recently treated two men with metastatic, castration-resistant prostate cancer (mCRPC) using chimeric antibody receptor T-cell therapy (CAR-T). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: antibody, CAR-T, chimeric, receptor, T-cell | 9 Comments »
On November 15, our friends at CureTalks will hold a telecon on which there will be a discussion about the current and potential future uses of CAR-T in the treatment of cancer with Prof. Carl June of the University of Pennsylvania. … READ MORE …
Filed under: Drugs in development | Tagged: antigen, CAR-T, chimeric, receptor, T-cell, therapy | Leave a comment »
A group at The Institute for Cancer Research and The Royal Marsden Hospital in the UK — along with other European colleagues — has come up with a new, relatively low-cost test that seems to be able to identify men with advanced forms of prostate cancer who are more or less likely to respond well to treatment with drugs like abirateone acetate and enzalutamide. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen, gene, receptor, resistance, test | 4 Comments »
As yet, there has been no serious clinical exploration of whether the new types of CAR-T treatment can be applied to patients with either prostate cancer or any other form of solid tumor. … READ MORE …
Filed under: Drugs in development | Tagged: antigen, CAR-T, chimeric, receptor, therapy | 2 Comments »
Most of our readers will be familiar with the idea that progression of prostate cancer over time is associated with the expression of androgen receptors (ARs) in prostate cancer tissue. … READ MORE …
Filed under: Drugs in development | Tagged: androgen, pathway, receptor, ROR-γ | 2 Comments »
A newly published paper in Science Translational Medicine has added to our understanding of the future potential of liquid biopsies (e.g., blood, plasma, and similar samples) in the management of progressive forms of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen, biopsy, expression, liquid, plasma, receptor | Leave a comment »
According to a media release today from Bayer HealthCare and Orion Corporation (a Finnish pharmaceutical company), they have started to enroll patients in a randomized Phase III clinical trial of ODM-201, a novel, oral androgen receptor inhibitor in development for the treatment of men with advanced forms of prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: androgen, castration-resistant, CRPC, inhibitor, ODM-201, receptor | 10 Comments »
Historically, it has generally been assumed that androgen receptor gene amplification was a result of androgen deprivation therapy (ADT) and occurred in some 20 to 30 percent of men with castration-resistant prostate cancer (CRPC). However, … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: amplification, androgen, early, gene, mortality, receptor, risk | 1 Comment »
An article just published in the British Journal of Cancer, has proposed that androgen receptor (AR) gene amplification may be a prime cause of treatment failure in a subset of men with progressive prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: amplification, androgen, gene, receptor, risk | Leave a comment »
Researchers from the Mayo Clinic in Rochester, MN, are claiming that they have made a series of four important discoveries related to the role of a protein called “speckle-type POZ protein” (SPOP) and its involvement in the development of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: androgen, protein, receptor, SPOP | Leave a comment »
The full text of a recent review on the use of LHRH receptor agonists (e.g., leuprolide acetate, goserelin acetate) asnd LHRH receptor antagonists (e.g., degarelix) has recently been published by Shore et al. in Prostate Cancer and Prostatic Diseases. The full text of the article is also available on line on the Medscape Oncology web site.
Filed under: Management, Treatment | Tagged: agonist, antagonist, LHRH, receptor, review | 3 Comments »
An article published on line in the Journal of Urology last Friday suggests that an enzyme known as G-protein-coupled receptor kinase 5 or GRK5 may have an important role in the regulation of the growth of prostate cancer. … READ MORE …
Filed under: Drugs in development | Tagged: G-protein, GRK5, kinase, receptor | Leave a comment »
A while back now the research group at M. D. Anderson Cancer Center initiated a Phase II clinical trial of a drug called tandutinib in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) who had already had taxane-based chemotherapy. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer | Tagged: castration-resistant, mCRPC, PDGF, PDGFR, platelet-derived growth factor, receptor, tandutinib | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 